MARKET WIREYahoo Finance UK • 17h ago
Royalty Pharma plc (RPRX) stock price, news, quote and historyYahoo Finance UK report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
Why RPRX Stock advanced +1.90% Today — RQD Quant Desk Flash
$67.18 +1.90% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $67.57
Royalty Pharma plc (Class A) (RPRX) earns a Roarable Rating of B+ (Buy) with 76/100 RQD Confidence. High-quality cash engine (steady margins, 7% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B+ • BUY
Cap $38.63B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on RPRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is RPRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Royalty Pharma plc (Class A) (NASDAQ: RPRX) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $67.18 (+1.90% 1D, market cap $38.63B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 19/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, RPRX ranks #29 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does RPRX compare to GMAB and ONC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RPRX carries a Roarable B+ (76/100 RQD), trailing P/E of 49.2x, gross margin of —, and ROIC of 7.0%. By comparison, GMAB (Genmab A/S ADS) holds a B- grade (70/100 RQD, P/E 32.8x, ROIC 9.9%, cap $35.61B) and ONC (BeOne Medicines Ltd.) posts a B- grade (71/100 RQD, P/E 147.2x, ROIC 10.5%, cap $42.11B). Among the 5-stock peer group, ZTS leads on earnings multiple (12.2x) while ZTS leads on capital efficiency (25.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for RPRX?
▼
Per RPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802768), Royalty Pharma plc (Class A) generated $2.38B in revenue (+5.1% YoY), $770.9M in net income, and $2.38B in free cash flow against $19.62B in total assets and $8.57B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Priced at 49x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $67.57 (+0.58%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 100.2% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 76/100 (B+) historically ranked in the Top 11% of excess returns over the next 90 days (+7.6% avg 90D alpha vs SPY • 70.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B+
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B+ · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+8.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RPRX)Realized 20D OHLCV Swing Band: ±4.8%
Deterministic 5-Pillar Attribution (76/100 Composite)
🔍 WHY RPRX SCORES 76/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+19/20 pts (25% of score)
20D Institutional Volume Accumulation (±4.8% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+16/20 pts (21% of score)
FRED Regime × Technicals: 98% of 52W Range • RSI-14 at 72 (OVERBOUGHT (>70))
▼ #1 Drag / Risk Factor: Cash Engine Quality13/20 pts (-7 pt drag)
Capital intensity & 52% operating margin leave 7 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$58.99+5.4% Next Q
68
Q2 (-2Q)Grade B$62.15+4.3% Next Q
71
Q3 (-1Q)Grade B$64.82+3.6% Next Q
73
CurrentGrade B+$67.18+7.6% Hist 90D α
76
Trajectory: B- (68) → B+ (76)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the RPRX Bull Thesis Could Fail
Even with a 76/100 (B+) score, RPRX faces multiple-compression risk if 49.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Priced at 49x earnings—high expectations leave less room for a lukewarm quarter.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($60.56) or 200D SMA ($53.63) invalidates the momentum regime and cuts Target Base ($72.62) toward Bear Floor ($55.09).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $RPRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RPRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why RPRX Stock advanced +1.90% Today — RQD Quant Desk Flash
Royalty Pharma plc (Class A) (RPRX) advanced +1.90% to $67.18, trading at 98% of its 52-week range ($36.03 – $67.71). High-quality cash engine (steady margins, 7% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 98% of its 52-week range ($36.03 – $67.71) with RSI-14 at 72 (OVERBOUGHT (>70)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4.8% around $67.18 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B+ (Buy) backed by 52% gross margin and $2.4B annual free cash flow.
Live RPRX Headlines & Catalysts
MARKET WIREThe Motley Fool • 20h ago
Should You Buy Royalty Pharma Stock Before Nov. 4?The Motley Fool report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 23h ago
Royalty Pharma (Nasdaq:RPRX) - Stock AnalysisSimply Wall St report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Royalty Pharma plc (RPRX) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much TodayBenzinga report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
CATALYSTMarketBeat • 1d ago
Royalty Pharma (NASDAQ:RPRX) Stock Jumps 3.3% - Here's WhyMarketBeat report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Royalty Pharma (RPRX), Why Is It Back In The Spotlight?Simply Wall St report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 3d ago
Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision NearsZenas BioPharma (NASDAQ:ZBIO) outlined development plans for obexelimab in systemic lupus erythematosus (SLE) and ZB021, an investigational oral IL-17AA/AF inhibitor, during an R&D event ahead of clinical data expected l
MARKET WIREYahoo • 3d ago
Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key MetricsBeyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended Septemb
CATALYSTYahoo • 4d ago
Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseGuardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (RPRX Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
RPRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +33.82%⚡ TESTING RESISTANCE
2026-11-03O $65.93H $67.18L $65.93C $67.18VOL 4.66M
RES: $67.97SUP: $54.62SMA50: $60.56SMA200: $53.63
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
RPRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
35.9%/yr Implied 5Y Growth
vs. +5.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on RPRX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for RPRX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RPRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RPRX)
Health Care Rank #29 of 1016
⚔️ GMAB vs RPRX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (RPRX vs. GMAB, ONC, ZTS, TEVA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Royalty Pharma plc (Class A) (RPRX) ranks #29 by composite RQD confidence (76/100, grade B+) and #47 by equity capitalization ($38.63B). Within this direct 5-issuer industry benchmark cohort, ZTS leads on earnings valuation at 12.2x trailing P/E, while ZTS leads on capital efficiency and profitability with 25.7% ROIC and 71.8% gross margin. RPRX currently leads its immediate peer cohort in composite quantitative strength at 76/100 (B+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RPRX
ACTIVE
Royalty Pharma plc (Class A) | B+ | 76/100 | 49.2x | — | 7.0% | +1.90% | $38.63B | Benchmark Subject |
| GMAB Genmab A/S ADS | B- | 70/100 | 32.8x | — | 9.9% | +1.01% | $35.61B | /gmab-vs-rprx → |
| ONC BeOne Medicines Ltd. | B- | 71/100 | 147.2x | 87.5% | 10.5% | -0.33% | $42.11B | /onc-vs-rprx → |
| ZTS Zoetis Inc. | C+ | 68/100 | 12.2x | 71.8% | 25.7% | +1.17% | $32.94B | /zts-vs-rprx → |
| TEVA Teva Pharmaceutical Industries Limited | C- | 61/100 | 34.3x | 51.8% | 9.4% | +1.50% | $49.05B | /teva-vs-rprx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001802768In its most recent audited fiscal period (FY2025, filed 2025-12-31), Royalty Pharma plc (Class A) (RPRX) reported GAAP revenue of $2.38B (+5.1% vs. FY2024 revenue of $2.26B , and +1.0% cumulative change since FY2023) , GAAP net income of $770.9M, operating cash flow of $2.49B, and free cash flow of $2.38B (-10.7% YoY). On the balance sheet, RPRX closed FY2025 with $19.62B in total assets against $8.57B in total debt (Altman Z-Score: 2.90, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.38B | $770.9M | $2.49B | $2.38B | $19.62B | $8.57B |
| FY2024 (FY) | 2024-12-31 | $2.26B | $859.0M | $2.77B | $2.67B | $18.22B | $6.61B |
| FY2023 (FY) | 2023-12-31 | $2.35B | $1.13B | $2.99B | $2.88B | $20.85B | $4.88B |
3. RPRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs RPRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Royalty Pharma plc (Class A) (NASDAQ: RPRX) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $67.18 (+1.90% 1D, market cap $38.63B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 19/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, RPRX ranks #29 in composite RQD confidence.
How does RPRX compare to GMAB and ONC in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RPRX carries a Roarable B+ (76/100 RQD), trailing P/E of 49.2x, gross margin of —, and ROIC of 7.0%. By comparison, GMAB (Genmab A/S ADS) holds a B- grade (70/100 RQD, P/E 32.8x, ROIC 9.9%, cap $35.61B) and ONC (BeOne Medicines Ltd.) posts a B- grade (71/100 RQD, P/E 147.2x, ROIC 10.5%, cap $42.11B). Among the 5-stock peer group, ZTS leads on earnings multiple (12.2x) while ZTS leads on capital efficiency (25.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for RPRX?
Per RPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802768), Royalty Pharma plc (Class A) generated $2.38B in revenue (+5.1% YoY), $770.9M in net income, and $2.38B in free cash flow against $19.62B in total assets and $8.57B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Priced at 49x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is RPRX trading relative to its 50-day, 200-day, and 52-week technical levels?
RPRX last traded at $67.18 (+1.90% on volume of 4,662,366 shares), positioning the stock +10.93% above its 50-day simple moving average ($60.56) and +25.27% above its 200-day simple moving average ($53.63). Across its 52-week range of $36.03 to $67.71, RPRX sits at the 98.3% percentile with a 14-day RSI of 72.0 (OVERBOUGHT (>70)) and an implied next-earnings move of ±4.8% ($63.96 to $70.40).
RPRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is RPRX stock moving today?
Why RPRX Stock advanced +1.90% Today — RQD Quant Desk Flash. High-quality cash engine (steady margins, 7% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 76/100 (B+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
RPRX — Royalty Pharma plc (Class A): What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:11:47Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, RPRX scores 75 out of 100, a letter grade of B, labeled "Roarable Buy — Good Risk/Reward." The five pillars are as follows:
- Fundamental Cash Engine (13 / 20): The rating cites ROIC of 7% and an FCF yield of 6.29%. This pillar is the rating's weakest link relative to its size, suggesting that the cash generation supports the valuation but does not fully justify it on a return-on-capital basis.
- Whale 13F Flow (18 / 20): Institutional accumulation and options positioning are scored strongly, the highest pillar in the rating. For a prospective investor, this indicates that large holders have been building positions, which can support demand but also means crowded positioning can reverse.
- Insider Conviction (14 / 20): SEC Form 4 and Congressional PTR cluster flow are scored moderately. The rating reflects some insider and congressional activity, though not an overwhelmingly one-directional signal.
- Macro Regime Fit (16 / 20): Beta of 0.94 and sector sensitivity place the stock near market-level volatility, which the rating treats as a favorable fit for current conditions.
- Forensic Balance Sheet (14 / 20): Altman Z of 2.9, Piotroski F of 8/9, and Debt/Equity of 0.88 indicate a financially sound profile with moderate leverage.
Investor implications: the rating's upside drivers are institutional demand and a balance sheet that scores well on forensic tests. The principal valuation tradeoff is visible in the market data: P/E (TTM) of 49.2 and Forward P/E of 45.8 are high, meaning the price already embeds substantial expectations relative to reported earnings. The rating's favorable grade therefore depends on sustained cash generation and institutional support rather than on current earnings multiples being cheap. This brief is educational and not personalized financial advice.
Snapshot
Business
Royalty Pharma plc (Class A Ordinary Shares, NASDAQ: RPRX) is classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, it is a publicly traded US issuer with a market capitalization of $37.9B. The source data does not describe its products, customers, or specific revenue model. Operating margin of 65.6% and net margin of 32.4% (per market data) are consistent with a high-margin, cash-generative business profile, but the source data does not state how the company earns that revenue.
Recent Catalysts & News Wire Analysis
The news wire contains six items, all relating to RPRX and none containing substantive operating detail. Items are headlined as stock-price and analysis coverage from Yahoo Finance UK, The Motley Fool, Simply Wall St, Yahoo! Finance Canada, Benzinga, and MarketBeat. One MarketBeat item is flagged as a "CATALYST" with a GREEN signal, headlined as a stock move of 3.3%. The Motley Fool item references a date of Nov. 4 in its headline. Other items are flagged YELLOW as market wire. The source summaries are generic and do not disclose specific catalyst events. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.
Risk watch items: the news summaries do not identify specific risks. Price action is reflected in the market data: the stock is at $65.93 with a 52-week range of $36.03 to $67.71, placing it near the top of that range.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, supply_chain is NONE and butterfly_links is empty. The graph does not identify upstream or downstream dependencies, sector correlations beyond the stated sector and industry, or second-order bottlenecks. A prospective investor should not infer supply-chain relationships from this data.
Open Questions
- What products or licensed assets generate the reported $2378.2M of FY 2025 revenue, and who are the principal counterparties?
- What explains the decline in net income from $1134.8M (FY 2023) to $770.9M (FY 2025) while operating income and FCF remained substantial?
- What drove the increase in debt from $4879.0M to $8570.9M, and what are its maturity profile and cost?
- Why is the gross margin reported as 0%, and how does that reconcile with the reported operating margin of 65.6%?
- Which specific events are behind the news items, including the item referencing Nov. 4, and what are the scheduled catalysts?
RPRX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Royalty Pharma plc (Class A) (RPRX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance UK • 17h ago
Royalty Pharma plc (RPRX) stock price, news, quote and history Yahoo Finance UK report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Motley Fool • 20h ago
Should You Buy Royalty Pharma Stock Before Nov. 4? The Motley Fool report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 23h ago
Royalty Pharma (Nasdaq:RPRX) - Stock Analysis Simply Wall St report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Royalty Pharma plc (RPRX) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today Benzinga report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST MarketBeat • 1d ago
Royalty Pharma (NASDAQ:RPRX) Stock Jumps 3.3% - Here's Why MarketBeat report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Royalty Pharma (RPRX), Why Is It Back In The Spotlight? Simply Wall St report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo • 3d ago
Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears Zenas BioPharma (NASDAQ:ZBIO) outlined development plans for obexelimab in systemic lupus erythematosus (SLE) and ZB021, an investigational oral IL-17AA/AF inhibitor, during an R&D event ahead of clinical data expected l
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
RPRX Bull vs. Bear Conversation Board — What's Your Call at $67.18?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RPRX 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $77.80 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is RPRX (B • RQD 75/100) a Buy at $65.93?
Welcome to the RPRX (Royalty Pharma plc (Class A)) Roar Pit. Current RQD Composite is 75/100 (Roarable Buy — Good Risk/Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (49.2x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $51.43 (-22.0%)
Spot @ $65.93 Pump the brakes on RPRX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on RPRX, but look at what you are paying: 49.2x trailing P/E with tightening sector spreads. Unless Royalty Pharma plc (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH
🎯 Target: $82.41 (+25.0%)
Spot @ $65.93 RPRX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on RPRX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $65.93 (52-wk range $36.03 - $67.71), any beat on forward guidance forces shorts and underweight funds to chase.